Juniper Pharmaceuticals, Inc. Common Stock
JNP
JNP was delisted on the 13th of August, 2018.
31 hedge funds and large institutions have $11M invested in Juniper Pharmaceuticals, Inc. Common Stock in 2013 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 10 increasing their positions, 6 reducing their positions, and 5 closing their positions.
380% more call options, than puts
Call options by funds: $264K | Put options by funds: $55K
67% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 6
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
9% more capital invested
Capital invested by funds: $10.1M → $11M (+$939K)
3% more funds holding
Funds holding: 30 → 31 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DMK
David M. Knott
|
+$1.09M |
| 2 |
WCM
Wedge Capital Management
Charlotte,
North Carolina
|
+$918K |
| 3 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$445K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$380K |
| 5 |
Morgan Stanley
New York
|
+$229K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NI
Numeric Investors
Boston,
Massachusetts
|
-$577K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$484K |
| 3 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$434K |
| 4 |
Renaissance Technologies
New York
|
-$141K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$27.7K |
JNP Hedge Fund Activity: Q4 2013 in Review
31 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Juniper Pharmaceuticals, Inc. Common Stock (JNP) for Q4 2013, worth a combined $11M — up 9.3% from $10.1M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new JNP positions and 5 closed out — a net gain of 1 holder — while 10 added to existing stakes and 6 trimmed.
The largest buyer was David M. Knott, opening a new position worth an estimated $1.09M. The largest seller was Numeric Investors, exiting entirely with an estimated $577K sold.
- 31 institutional investors held Juniper Pharmaceuticals, Inc. Common Stock (JNP) as of Q4 2013, up from 30 in Q3 2013.
- Funds reported $11M of Juniper Pharmaceuticals, Inc. Common Stock stock for Q4 2013, up 9.3% quarter-over-quarter.
- 6 funds opened new Juniper Pharmaceuticals, Inc. Common Stock positions in Q4 2013 and 5 closed out, a net change of +1 holder.
- The largest Juniper Pharmaceuticals, Inc. Common Stock buyer in Q4 2013 was David M. Knott, an estimated $1.09M added.
- The largest Juniper Pharmaceuticals, Inc. Common Stock seller in Q4 2013 was Numeric Investors, an estimated $577K sold.
Based on aggregated 13F filings for Q4 2013.